MSMax Shin

Max Shin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Max Shin has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 March 2026
      • Vol. 40  (3) , e70452
    Open Access

    Impact of Prolonged Impella 5.5 Support on Post-Transplant Outcomes: An Institutional Study.

    by David Rekhtman, Amit Iyengar, Cindy Song, Michaela Asher, Max Shin, Michael Catalano, Omar Toubat, Emma Morganroth, Alyson Brown, Joyce Wald, et al.

    Microaxial flow pump devices are utilized as a bridge to heart transplantation for patients in advanced cardiogenic shock. Little is known about the impact of device duration on post-transplant outcomes. This study aims to compare post-transplantation outcomes based on duration of support with the Impella 5.5. All patients who were successfully bridged to transplant on the Impella 5.5 platform were included and stratified based on support duration (≤ 14 days vs. > 14 days). Baseline clinical characteristics were collected throughout the index admission. Outcomes included 1-year mortality, complications during the index admission, graft rejection, and rehospitalization within the first year. Of the 72 patients successfully bridged to transplant, 64% (n = 46) were supported for more than 14 days. When stratified by duration of Impella 5.5 use, there were no differences in pretransplantation clinical status. Length of stay (26 vs. 20 days, p = 0.316) and rates of home discharges (65% vs. 67%, p = 0.524) were similar. Despite a high prevalence of rehospitalization at 1 year (75%), the 1-year survival was 96% and similar between the two cohorts (p = 0.289). Use of a prolonged microaxial flow pump may be a safe bridging strategy for heart transplantation given comparable post-transplant outcomes for patients stratified by support duration.

  • Open Access

    Impact of Prolonged Impella 5.5 Support on Post‐Transplant Outcomes: An Institutional Study

    by David Rekhtman, Amit Iyengar, Cindy Song, Michaela Asher, Max Shin, Michael Catalano, Omar Toubat, Emma Morganroth, Alyson Brown, Joyce Wald, et al.

    Objectives: Microaxial flow pump devices are utilized as a bridge to heart transplantation for patients in advanced cardiogenic shock. Little is known about the impact of device duration on post‐transplant outcomes. This study aims to compare post‐transplantation outcomes based on duration of support with the Impella 5.5. Methods: All patients who were successfully bridged to transplant on the Impella 5.5 platform were included and stratified based on support duration (≤ 14 days vs. > 14 days). Baseline clinical characteristics were collected throughout the index admission. Outcomes included 1‐year mortality, complications during the index admission, graft rejection, and rehospitalization within the first year. Results: Of the 72 patients successfully bridged to transplant, 64% (n = 46) were supported for more than 14 days. When stratified by duration of Impella 5.5 use, there were no differences in pretransplantation clinical status. Length of stay (26 vs. 20 days, p = 0.316) and rates of home discharges (65% vs. 67%, p = 0.524) were similar. Despite a high prevalence of rehospitalization at 1 year (75%), the 1‐year survival was 96% and similar between the two cohorts ( p = 0.289). Conclusions: Use of a prolonged microaxial flow pump may be a safe bridging strategy for heart transplantation given comparable post‐transplant outcomes for patients stratified by support duration.


  • Open Access

    Listing for Pediatric Donation After Circulatory Death Heart Transplantation Is Associated With Improved Waitlist Outcomes

    by Michael A. Catalano, Max Shin, Omar Toubat, Radhika Rastogi, Halil Beqaj, Amit Iyengar, Benjamin F. Smood, Nikia Toomey, Jonathan B. Edelson, Joseph W. Rossano, et al.

    Background: Advances in procurement techniques have enabled use of hearts obtained via donation after circulatory death (DCD), expanding the donor pool; however, the impact of DCD heart transplant on outcomes in children is not well described. We aim to characterize waitlist survival and outcomes in pediatric heart transplant candidates listed for donation after brain death (DBD) versus DCD hearts. Methods: The United Network for Organ Sharing database was queried for patients aged P =0.01). No patients in the status 1B/2 DCD subgroup died while waitlisted. There were no differences in 1‐year posttransplant survival. Conclusions: Among candidates for pediatric heart transplant listed as status 1B/2, patients listed for DCD hearts in addition to DBD hearts have shorter waitlist duration, improved transplant rates, lower waitlist mortality rates, and comparable survival to patients listed for DBD hearts alone.


  • Acute Hemodynamic and Echocardiographic Consequences of Impella 5.5 Placement in Patients With Advanced Cardiogenic Shock

    by Michaela Asher, Amit Iyengar, David Rekhtman, Mark Helmers, Noah Weingarten, Cindy Song, John DePaolo, Max Shin, Alyson Brown, Joyce Wald, et al.

    We sought to investigate the hemodynamic and echocardiographic consequences of the Impella 5.5 during the acute perioperative period. A retrospective analysis of patients who underwent device implantation at our institution between January 2021 and June 2023 was performed. Hemodynamic and echocardiographic changes were modeled as linear mixed models with random intercepts for patient and fixed as well as random effects of time. Of 87 patients identified, most were male (72, 83%) with nonischemic cardiomyopathy (44, 51%). In the first two postoperative days, the median cardiac output increased by 1.2 L/min (p < 0.05), although the median Impella flow remained at 4.1 L/min. Mean pulmonary artery pressures (32 vs. 27 mm Hg, p < 0.05) and vasoactive inotrope scores (5.6 vs. 3.7, p < 0.01) were modestly reduced. Significant echocardiographic improvement was noted in 61% and 71% of patients with significant preoperative mitral or tricuspid regurgitation, respectively. However, no changes in ejection fraction, left ventricle (LV) diameter, or right ventricular function were noted (all p > 0.05). At 30 days, 27 (31%) patients were transplanted and 13 (15%) were bridged to a durable left ventricular assist device (LVAD). We conclude that in the acute phase following Impella implantation, LV offloading, reductions in pulmonary artery pressures, and improvement in valvular regurgitation are seen without changes to ventricular geometry.


  • Open Access

    Outcomes of COVID‐19–Positive Donor Heart Transplantation in the United States

    by Samuel T. Kim, Amit Iyengar, Mark R. Helmers, Noah Weingarten, David Rekhtman, Cindy Song, Max Shin, Marisa Cevasco, Pavan Atluri

    Background: Little is known regarding the impact of donor COVID‐19 status on recipient outcomes after heart transplantation. In this study, we characterize outcomes of the first 110 heart transplants from organ donors positive for COVID‐19 (COVID‐19+) in the United States. Methods and Results: Retrospective analysis of the United Network for Organ Sharing database was performed for single‐organ adult heart transplants from January 2020 to March 2022. Donor COVID‐19+ status was defined as a positive nucleic acid amplification, antigen, or other COVID‐19 test within 7 days of transplant. Nearest‐neighbor propensity score matching used to adjust for differences between recipients of COVID‐19+ and nonpositive donor hearts. Overall, 7251 heart transplants were included in analysis, with 110 using COVID‐19+ donor hearts. Recipients of COVID‐19+ allografts were younger (54 [interquartile range, 41–61]) versus 57 [46–64] years; P =0.02) but had similar rates of female sex and non‐White race compared with those receiving allografts from negative donors. Nearest‐neighbor propensity score matching resulted in 100 well‐matched pairs of recipients of COVID‐19+ versus nonpositive donor organs. The 2 matched groups had similar median lengths of stay (15 [11–23] days versus 15 [13–23] days; P =0.40), rates of graft failure (1% versus 0%; P =0.99), 30‐day death (3% versus 3%; P =0.99), and 3‐month survival (88% versus 94%; P =0.23) compared with recipients of nonpositive donors. No deaths occurred due to COVID‐19 infection among the 8 (7%) total deceased recipients of COVID‐19+ allografts to date. Conclusions: Short‐term outcomes of heart transplant recipients receiving COVID‐19+ donor organs are reassuring. However, continued monitoring for long‐term survival and potential complications are warranted.


  • Impella 5.5 as a bridge to heart transplantation: Waitlist outcomes in the United States

    by Marisa Cevasco, Max Shin, William Cohen, Mark R. Helmers, Noah Weingarten, David Rekhtman, Joyce W. Wald, Amit Iyengar

    Objectives: The 2018 United Network for Organ Sharing allocation policy change has led to a significant increase in the use of mechanical circulatory support devices in patients listed for orthotopic heart transplantation. However, there has been a paucity of data regarding the newest generation Impella 5.5, which received FDA approval in 2019.Methods: The United Network for Organ Sharing registry was queried for all adults awaiting orthotopic heart transplantation who received Impella 5.5 support during their listing period. Waitlist, device, and early post‐transplant outcomes were assessed.Results: A total of 464 patients received Impella 5.5 support during their listing period with a median waitlist time of 19 days. Among them, 402 (87%) patients were ultimately transplanted, with 378 (81%) being directly bridged to transplant with the device. Waitlist death (7%) and clinical deterioration (5%) were the most common reasons for waitlist removal. Device complications and failure were uncommon (<5%). The most common post‐transplant complication was acute kidney injury requiring dialysis (16%). Survival at 1‐year post‐transplant survival was 89.5%.Conclusion: Since its approval, the Impella 5.5 has been increasingly used as a bridge to transplant. This analysis demonstrates robust waitlist and post‐transplant outcomes with minimal device‐related and postoperative complications.


  • Higher Rates of Dialysis and Subsequent Mortality in the New Allocation Era for Heart Transplants

    by Max Shin, Jason J. Han, William G. Cohen, Amit Iyengar, Mark R. Helmers, John J. Kelly, William L. Patrick, Xingmei Wang, Marisa Cevasco


  • Appraisal of clinical practice guidelines for the evaluation and management of neck masses in children

    by Max Shin, Aman Prasad, Gabriel R Arguelles, Jonathan J Wakim, Kevin Chorath, Alvaro Moreira, Karthik Rajasekaran

    Aim: The purpose of this systematic review was to use the Appraisal of Guidelines for Research and Evaluation tool to assess the methodological quality of clinical practice guidelines (CPGs) for the workup and management of paediatric neck masses.Methods: MEDLINE, Embase, Cochrane and grey literature were searched to identify CPG incorporating paediatric neck masses. Four authors with previous training of the Appraisal of Guidelines for Research and Evaluation tool evaluated the included studies.Results: Nine studies met inclusion criteria. The highest scoring domains were ‘Scope and Purpose’ (74.0 ± 4.5) and ‘Clarity of Presentation’ (72.9 ± 6.3). The lowest scoring domains were ‘Rigour and Development’ (18.8 ± 7.5) and ‘Applicability’ (23.7 ± 6.1). One study was ‘High’ quality, three received scores of ‘Average’ and five were found to be ‘Low’ quality.Conclusion: The majority of paediatric neck mass CPGs were low to average quality. The domains in need of greatest improvement were ‘Rigour and Development’ and ‘Applicability’, suggesting significant concerns in current CPGs focused on paediatric neck masses.


  • Telehealth Utilization in Response to the COVID-19 Pandemic in Pediatric Orthopaedic Surgery

    by Robert L. Parisien, Max Shin, David P. Trofa, Aman Prasad, Xinning Li, William N. Levine, John M. Flynn, Theodore J. Ganley

    Introduction: The purpose of this investigation was to assess the utilization of telehealth capabilities by pediatric orthopaedic departments across the United States in response to the COVID-19 pandemic. Methods: One hundred four pediatric orthopaedic departments were investigated regarding each institution's current telehealth utilization as a direct response to the COVID-19 pandemic. Results: Of the 104 hospitals contacted across the United States, 100 pediatric orthopaedic departments in 39 states responded for an overall response rate of 96%. Of the 95 institutions offering telehealth services, 83 (87.4%) cited the COVID-19 pandemic as the impetus for the implementation of telehealth services. Of these, 29 institutions (31%) began offering services from March 16 to March 31 and 34 (36%) began offering services from April 1 to April 15. Regional analysis demonstrated an 800% increase in telehealth services in the state of New York, a 600% increase in Florida, a 500% increase in Texas, a 400% increase in Michigan, a 200% increase in Pennsylvania, and a 1,100% increase in California. Discussion: This study demonstrates the rapid response measures instituted by pediatric orthopaedic institutions to meet the fundamental needs of the pediatric population during this unprecedented pandemic.


  • Open Access

    Complications, Reoperations, and Mid-Term Outcomes Following Anterior Vertebral Body Tethering Versus Posterior Spinal Fusion

    by Max Shin, Gabriel R. Arguelles, Patrick J. Cahill, John M. Flynn, Keith D. Baldwin, Jason B. Anari

    Background: Anterior vertebral body tethering (AVBT) is a growth-modulation technique theorized to correct adolescent idiopathic scoliosis (AIS) without the postoperative stiffness imposed by posterior spinal fusion. However, data are limited to small series examining short-term outcomes. To assess AVBT’s potential as a viable alternative to posterior spinal fusion (PSF), a comprehensive comparison is warranted. The purpose of this meta-analysis was to compare postoperative outcomes between patients with AIS undergoing PSF and AVBT. Our primary objective was to compare complication and reoperation rates at available follow-up times. Secondary objectives included comparing mid-term Scoliosis Research Society (SRS)-22 scores, and coronal and sagittal-plane Cobb angle corrections. Methods: We performed a systematic review of outcome studies following AVBT and/or PSF procedures. The inclusion criteria included the following: AVBT and/or PSF procedures; Lenke 1 or 2 curves; an age of 10 to 18 years for >90% of the patient population; <10% non-AIS scoliosis etiology; and follow-up of ≥1 year. A single-arm, random-effects meta-analysis was performed. Deformity corrections, complication and reoperation rates, and postoperative SRS-22 scores were recorded. Results: Ten AVBT studies (211 patients) and 14 PSF studies (1,069 patients) were included. The mean follow-up durations were similar for both groups. Pooled complication rates were 26% for AVBT versus 2% for PSF, and reoperation rates were 14.1% for AVBT versus 0.6% for PSF with nonoverlapping confidence intervals (CIs). The pooled reoperation rate among studies with follow-up times of ≥36 months was 24.7% in AVBT versus 1.8% in PSF. Deformity correction, clinical outcomes, and mid-term SRS-22 scores were similar. Conclusions: Our study showed greater rates of complications and reoperations with AVBT compared with PSF. Reoperation rates were significantly greater in AVBT studies with longer follow-up (≥36 months). Deformity correction, clinical outcomes, and mid-term SRS-22 scores were similar. While a potential fusionless treatment for AIS merits excitement, clinicians should consider AVBT with caution. Future long-term randomized prospective studies are needed. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.